ArticleInvestigative ophthalmology & visual science2025
Insights Into the FOXE3 Transcriptional Network and Disease Mechanisms From the Investigation of a Regulatory Variant Driving Complex Microphthalmia.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unveiling ocular developmental disorders through short-read whole-genome sequencing.European journal of human genetics : EJHG · 2026Article
- A structure-guided approach to noncoding variant evaluation for transcription factor binding using AlphaFold 3.Nucleic acids research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: FOXE3 encodes a highly conserved, lens-enriched transcription factor essential for eye development. Biallelic mutations in FOXE3 are associated with a spectrum of ocular anomalies, ranging from congenital cataracts to complex microphthalmia (CM), with severity and penetrance correlating with genotype. This study aimed to investigate the regulatory landscape of FOXE3 and its contribution to CM. Methods: In a patient with CM, a truncating FOXE3 variation (p.Cys240*) was identified alongside a second, trans-acting regulatory variant (rv: rs745674596G>A) located 3 kb upstream of FOXE3. To investigate its functional impact, mouse models were generated carrying either the rv or a frameshift (fs) mutation in homozygosity (Foxe3rv/rv, Foxe3fs/fs) or in compound heterozygosity (Foxe3rv/fs). Ocular phenotypes were characterized, and molecular analyses were conducted to assess FOXE3 expression and transcriptional regulation. Results: Phenotypic severity followed a progressive pattern from Foxe3rv/rv to Foxe3rv/fs, with Foxe3fs/fs consistently exhibiting CM, mirroring genotype-dependent effects observed in humans. Protein levels, but not mRNA levels, correlated with ocular phenotype, with the frameshift mutation leading to pronounced mRNA overexpression in embryos. In Foxe3fs/fs mice, CM resulted from early anterior lens epithelium disorganization, triggering progressive lens degeneration and ocular involution. Transcription factor binding studies identified USF2 as a key regulator of FOXE3 expression, positioning it as a novel candidate in ocular development and disease. Conclusions: This study highlights the critical role of regulatory variants in ocular pathology, proposes a potentially novel mechanism for microphthalmia through lens degeneration, and identifies USF2 as a potential contributor to the FOXE3-regulatory network that remains largely unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.